



PHARMACEUTICAL 2022











PHARMACEUTICAL 2022



Pulmatrix Inc. Rank 181 of 466

The relative strengths and weaknesses of Pulmatrix Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Pulmatrix Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 49% points. The greatest weakness of Pulmatrix Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 18% points.

The company's Economic Capital Ratio, given in the ranking table, is 175%, being 97% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	54,778
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,442
Liabilities, Non-Current	857
Other Assets	3,718
Other Compr. Net Income	0
Other Expenses	3,577
Other Liabilities	6,069
Other Net Income	-4.0
Other Revenues	5,169
Property and Equipment	321
Research and Development	15,382
Selling, General and Administrative Expense	6,377

Output Variable	Value in 1000 USD
Assets	58,817
Liabilities	11,368
Expenses	25,336
Revenues	5,169
Stockholders Equity	47,449
Net Income	-20,171
Comprehensive Net Income	-20,171
Economic Capital Ratio	175%

